{"id":"NCT00712920","sponsor":"Meda Pharmaceuticals","briefTitle":"A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Perennial Allergies","officialTitle":"Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of MP03-36 and MP03-33 in Patients With Perennial Allergic Rhinitis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-01","primaryCompletion":"2008-05","completion":null,"firstPosted":"2008-07-10","resultsPosted":"2010-01-15","lastUpdate":"2011-06-08"},"enrollment":581,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Perennial Allergic Rhinitis"],"interventions":[{"type":"DRUG","name":"0.15% azelastine hydrochloride","otherNames":[]},{"type":"DRUG","name":"0.1% azelastine hydrochloride","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"1","type":"PLACEBO_COMPARATOR"},{"label":"2","type":"EXPERIMENTAL"},{"label":"3","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to determine if two allergy medications are more effective than placebo.","primaryOutcome":{"measure":"Change From Baseline in 12-hour Reflective Total Nasal Symptom Score (AM and PM Combined) at 28 Days.","timeFrame":"baseline and 28 days","effectByArm":[{"arm":"Placebo","deltaMin":14.7,"sd":0},{"arm":"Astepro 0.1%","deltaMin":15.5,"sd":0},{"arm":"Astepro 0.15%","deltaMin":15.8,"sd":0}],"pValues":[{"comp":"OG000 vs OG002","p":"0.03"},{"comp":"OG000 vs OG001","p":"0.08"}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":18},"locations":{"siteCount":43,"countries":["United States"]},"refs":{"pmids":["37920410"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":192},"commonTop":["Nasal Discomfort","Dysgesusia","Headache","Epistaxis","Upper Respiratory Tract Infection"]}}